MD Anderson Cancer Center Postgraduate Physician Assistant Fellowship in Oncology
Accreditation History

First accredited: June 2022
Next review: June 2025
Maximum class size per cohort: 3
Number of cohorts per year: 1
Page 1 of 1

June 2023
The commission Accepted the report providing evidence of
- defining and publishing admission practices that align with the admission decisions
No further information requested.

March 2023
- **Standard A4.06** (lacked evidence the program clearly defines and publishes the admission requirements and practices upon which admissions decisions are made),
- **Standard C1.01a** (provided evidence the program defines its ongoing self-assessment process to include administrative aspects of the program and institutional resources),
- **Standard C1.01e** (provided evidence the program defines its ongoing self-assessment process to include sufficiency and effectiveness of program instructional faculty and staff), and
- **Standard C2.01** (provided evidence the program implements its defined process for initial and ongoing evaluation of clinical sites).

Additional information (define and publish admission practices that align with the admission decisions) due May 5, 2023

June 2022
Accreditation-Clinical Postgraduate Program; Next Comprehensive Evaluation June 2025. The program is approved for up to three (3) students per cohort with one (1) entering cohort per year.
Report due December 1, 2022 (*Standards*, 3rd edition) -
- **Standard A4.06** (lacked evidence the program clearly defines and publishes the admission requirements and practices upon which admissions decisions are made),
- **Standard C1.01a** (lacked evidence the program defines its ongoing self-assessment process to include administrative aspects of the program and institutional resources),
- **Standard C1.01e** (lacked evidence the program defines its ongoing self-assessment process to include sufficiency and effectiveness of program instructional faculty and staff), and
- **Standard C2.01** (lacked evidence the program implements its defined process for initial and ongoing evaluation of clinical sites).